SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue zoomed 13.08% to Rs. 8367.60 millions for the quarter ended September 2023 as compared to Rs. 7399.60 millions during the corresponding quarter last year.The company has announced a 48.40% increase in its profits to Rs . 1450.20  millions for the  quarter ended September 2023 compared to Rs. 977.20 millions in the corresponding quarter in the previous year.Operating profit for the quarter ended September 2023 rose to 2416.80 millions as compared to 1675.10 millions of corresponding quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 8367.60 7399.60 13.08 16893.40 14560.90 16.02 28841.60 21898.80 31.70
Other Income 68.40 17.20 297.67 119.70 22.30 436.77 86.50 386.10 -77.60
PBIDT 2416.80 1675.10 44.28 4816.40 3360.00 43.35 6733.40 5475.20 22.98
Interest 94.60 76.00 24.47 206.70 133.90 54.37 343.10 49.50 593.13
PBDT 2322.20 1599.10 45.22 4609.70 3226.10 42.89 6390.30 5425.70 17.78
Depreciation 315.00 277.10 13.68 621.50 534.00 16.39 1119.90 712.80 57.11
PBT 2007.20 1322.00 51.83 3988.20 2692.10 48.14 5270.40 4712.90 11.83
TAX 557.00 344.80 61.54 1092.30 702.00 55.60 1381.50 1102.90 25.26
Deferred Tax 132.70 111.30 19.23 265.70 228.50 16.28 548.00 -122.10 -548.81
PAT 1450.20 977.20 48.40 2895.90 1990.10 45.52 3888.90 3610.00 7.73
Equity 155.00 154.70 0.19 155.00 154.70 0.19 154.80 154.60 0.13
PBIDTM(%) 28.88 22.64 27.59 28.51 23.08 23.55 23.35 25.00 -6.62

JB Chem & Pharma Share Price

2011.95 37.60 (1.90%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×